NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF OLAPARIB IN PATIENTS WITH TUMORS HARBORING DEFECTS IN DNA DAMAGE REPAIR GENES | NYU Langone Health

Go Back to All Clinical Trials

NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF OLAPARIB IN PATIENTS WITH TUMORS HARBORING DEFECTS IN DNA DAMAGE REPAIR GENES

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Refractory Solid Tumors
Age: Between 1 years - 21 years
Gender: Male or Female

Other Inclusion Criteria:

1)Patient must have enrolled onto APEC1621SC. 2)Patients must have a body surface area = 0.65 m2 at enrollment. 3)Patients must have radiographically measurable disease.

You may not be eligible for this study if the following are true:

1) Patients who are currently receiving another investigational drug or anti cancer agents are not eligible. 2) Patients who have an uncontrolled infection are not eligible. 3) Patients who are known to be tested positive for human immunodeficiency virus (HIV).